ClinicalTrials.gg
CompletedNCT00220779PRIVIGUpdated Apr 27, 2016Results posted

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

A Phase 2 interventional study of Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified and Albumin (Human) 25%, United States Pharmacopeia (USP) in Multiple Sclerosis, Relapsing-Remitting, sponsored by Grifols Therapeutics LLC. Completed at 37 sites in 12 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-04-27.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 106 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Germany — 4 open to participants now, 9 under way, 5 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Germany.

Enrollment
58th of 87
128 · median 214
Started
2002
with 1 other
Phase 2
27 of 106
none open now
Registered
6th of 106
by date

Among the 106 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Germany, this one is the 58th largest by enrollment of the 87 interventional ones that give a count, is one of 2 that started in 2002, is one of 27 in phase 2, and was the 6th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

4 of the 106 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Germany, or all of them as a file.
02

Study summary

The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.

Read the detailed description

This trial is designed as a multi-national, randomized, double-blind, placebo-controlled prospective trial with three parallel groups.

One hundred twenty (120) patients, 40 per treatment arm, with relapsing-remitting (RR) multiple sclerosis will be enrolled in this trial. Eligible patients must have a diagnosis of MS as per the McDonald Criteria. In addition, patients must have a diagnosis of relapsing-remitting course of MS defined as periods of worsening of neurological function with full recovery or with sequelae and residual deficit upon recovery; periods between disease relapses characterized by lack of disease progression. Patients must also have active disease with at least 1 defined documented relapse in the last year.

During a 2 month run-in period, 2 MRIs will be performed 6 weeks apart and patients will be stratified based on the presence or absence of 1 or more Gadolinium enhancing lesions on the first MRI (Gd-enhancing lesion yes-no) and will be randomized to one of two dose regimens of IGIV-C or matching placebo. Patients will receive study drug infusions every 4 weeks for 48 weeks for a total of 12 infusions. Patients will be evaluated by MRI every 6 weeks and by clinical assessments every 3 months. A follow-up visit will occur 4 weeks after the last infusion.

The treatment groups are as follows:

  • IGIV-C - 0.2 g/kg body weight (bw)/infusion (2 ml/kg bw)
  • IGIV-C - 0.4 g/kg bw/infusion (4 ml/kg bw)
  • placebo (0.1% albumin) - 4 ml/kg bw/infusion

For blinding purposes, at each infusion, all patients will receive a total volume of 4 ml/kg bw. For patients receiving 0.2 g/kg bw of IGIV-C, the final volume of 4 ml/kg bw will be adjusted by the addition of dextrose 5%. Placebo will be supplied as Albumin 5% or Albumin 25% and diluted with either dextrose 5% or saline to a final concentration of 0.1% albumin.

Dose adaptation will be performed for subsequent infusions in case the patient's body weight has changed > 10%. The maximum amount available per infusion will be 400 ml (8 vials) calculated for a patient with a body weight of 100 kg. The suggested initial infusion rate will be 0.02 ml/kg/min for the first 15 minutes. If there is no evidence of a hypersensitivity reaction, the infusion may be given at a slowly increasing rate over the next 30 minutes up to a maximum allowable rate of 0.08 ml/kg/min. As such, the infusion for a 70 kg patient will take approximately 1hour 15 min. The overall infusion time may have a range from 1 to 2 hours.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptoms consistent with Multiple Sclerosis up to 5 years
  • Diagnosis of multiple sclerosis according to McDonald criteria.
  • Diagnosis of relapsing-remitting (RR) multiple sclerosis (MS) (Defined as periods of worsening of neurological function with full recovery or with sequelae and residual deficit upon recovery; periods between disease relapses characterized by lack of disease progression
  • Kurtzke Extended Disability Status Scale (EDSS) \< 5.0
  • At least 1 defined and documented relapse during the last year. Prior relapses where symptoms were due solely to a change in Bowel/Bladder Function or Cognitive Function will not be considered relapses as defined by this protocol and therefore not counted for inclusion into the study.
  • Females or males; females of must use adequate
  • Clinically stable for at least 30 days prior to entry
  • At least 9 hyperintense T2 lesions on MRI or 1 Gd-enhancing lesion according to McDonald/Barkhof dissemination-in-space criteria at entry
  • Patients who have been informed about available treatments and decided, not to go on these treatments
  • Written obtained prior to the initiation of any study related procedures

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, breast feeding, or if, of , unwilling to practice adequate throughout the study
  • Prior therapy with azathioprine or any agents within 6 months prior to study entry
  • Prior , methylprednisolone or adrenocorticotropic hormone (ACTH) therapy within 30 days prior to study entry
  • Therapy with interferons (Betaseron®, Avonex®, Rebif®), glatiramer acetate (Copaxone®) or IGIV within 3 months prior to study entry or during the study
  • Use of an compound within 6 months prior to study entry
  • Previous lymphoid irradiation or prior to treatment with cyclophosphamide, methotrexate or mitoxantrone
  • Cardiac insufficiency ( III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease (CCS III or IV), or malignant hypertension
  • History of renal insufficiency or serum creatinine levels greater than 2.5 mg/dL (221 µmol/L)
  • Known selective immunoglobulin A (IgA) deficiency or known antibodies to IgA
  • Conditions whose symptoms and effects could alter protein catabolism and/or immunoglobulin G (IgG) utilization (e.g., protein-losing enteropathies, nephrotic syndrome)
  • Any medical, psychiatric or other circumstances which impede or restrict the patient's participation in the study or any to contrast enhanced MRI (e.g.,pacemaker, aortic clip or any metal implant)
  • Patients with medical conditions including, but not limited to cardiac, pulmonary, hepatic, hematological (e.g. known coagulation disorder, history of deep venous thrombosis and/or pulmonary embolism), endocrine,or renal dysfunction, disorders, severe environmental allergies or chronic infections
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Group 1

    IGIV-C 0.2 g/kg bw/infusion (2 ml/kg bw)

    Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified

  • Experimental
    Group 2

    IGIV-C 0.4 g/kg bw/infusion (4 ml/kg bw)

    Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified

  • Placebo comparator
    Group 3

    placebo (0.1% albumin) 4 ml/kg bw/infusion

    Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)

Interventions

  • DrugImmune Globulin IV [Human], 10% Caprylate/Chromatography Purified

    Drug page: Immunoglobulins, Intravenous

    Also known as: Gamunex®, IGIVnex®, Gaminex, IGIV-C, Immune Globulin Intravenous (Human) , 10%, IGIV, BAY 41-1000, TAL-05-00004, IGIV-C, 10%, IVIG, Immune Globulin (Human), 10% (IGIV), Immune Globulin Intravenous, 10% by Chromatography Process, NDC 13533-645-12, NDC 13533-645-15, NDC 13533-645-20, NDC 13533-645-24, NDC 13533-645-71

  • DrugAlbumin (Human) 25%, United States Pharmacopeia (USP)

    Also known as: Plasbumin®-5, Plasbumin®-25, Plasbumin®-5 (Low Aluminum), Plasbumin®-25 (Low Aluminum), Albumin (Human) 5%, USP, Albumin (Human) 25%, USP, TAL-05-00009, TAL-05-00023, TAL-05-00025, TAL-05-00026, BAY 34-9255, NDC 13533-684-16, NDC 13533-684-25, NDC 13533-684-71, NDC 13533-685-20, NDC 13533-685-25, NDC 13533-685-27, NDC 13533-690-20, NDC 13533-690-25, NDC 13533-690-27, NDC 13533-692-16, NDC 13533-692-20, NDC 13533-692-71

06

What researchers measure

Primary outcomes

  1. Percentage of Relapse Free Subjects (no Relapse)

    A relapse was defined for the purposes of this study as the appearance or reappearance of one or more neurological symptoms or worsening of an old symptom attributed to multiple sclerosis (MS) persisting for at least 48 hours and immediately preceded by a relatively stable or improving neurological state of at least 30 days.

    Time frame: 12 months

Secondary outcomes

  1. Effect on the Combined Unique Lesion Activity on Magnetic Resonance Imaging (MRI)

    Time frame: 1 year

07

Results

Posted Apr 11, 2014

Participant flow

The study was conducted in 31 study centers in Austria, Canada, Czech Republic, Germany, United Kingdom, Greece, Hungary, Israel, Poland, and the United States.

Participant flow — Overall Study
MilestoneIGIV-C 0.2 g/kg bw/Infusion (2 mL/kg Body Weight)IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg Body Weight)Placebo (0.1% Albumin) 4 mL/kg Body Weight/Infusion
Started454241
Completed383837
Not completed744
Withdrew: Adverse event100
Withdrew: Withdrawal by subject141
Withdrew: Non-compliance100
Withdrew: Too time consuming100
Withdrew: Pregnancy002
Withdrew: Lack of efficacy301

Outcome measures

SecondaryEffect on the Combined Unique Lesion Activity on Magnetic Resonance Imaging (MRI)
Time frame:
1 year

Results for this outcome have not been posted.

PrimaryPercentage of Relapse Free Subjects (no Relapse)

A relapse was defined for the purposes of this study as the appearance or reappearance of one or more neurological symptoms or worsening of an old symptom attributed to multiple sclerosis (MS) persisting for at least 48 hours and immediately preceded by a relatively stable or improving neurological state of at least 30 days.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Relapse Free Subjects (no Relapse)
percentage of participantsIGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw)IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw)Placebo (0.1% Albumin) 4 mL/kg bw/Infusion
No Relapse56.859.568.3
At Least One Relapse43.240.531.7
Statistical analysis
  • IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw) vs Placebo (0.1% Albumin) 4 mL/kg bw/Infusion · Cochran-Mantel-Haenszel · p = 0.221 (0.2g/kg IGIV Group versus Placebo)
  • IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw) vs Placebo (0.1% Albumin) 4 mL/kg bw/Infusion · Cochran-Mantel-Haenszel · p = 0.471 (0.4 g/kg IGIV Group versus Placebo)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw)—2/45 (4.4%)32/45 (71.1%)
IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw)—2/42 (4.8%)26/42 (61.9%)
Placebo (0.1% Albumin) 4 mL/kg bw/Infusion—1/41 (2.4%)29/41 (70.7%)
Most frequent serious events
Most frequent serious events
EventIGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw)IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw)Placebo (0.1% Albumin) 4 mL/kg bw/Infusion
ToothacheGeneral disorders0/450/421/41
Vasculitis, peripheralVascular disorders0/451/420/41
Panic attacksPsychiatric disorders0/451/420/41
HeadacheGeneral disorders1/450/420/41
Herpes Zoster ophthalmicEye disorders1/450/420/41
Most frequent other events
Showing 10 of 23
Most frequent other events
EventIGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw)IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw)Placebo (0.1% Albumin) 4 mL/kg bw/Infusion
NasopharyngitisInfections and infestations9/457/4211/41
RhinitisInfections and infestations3/457/424/41
HeadacheNervous system disorders7/455/426/41
Urinary tract infectionInfections and infestations1/456/422/41
FatigueGeneral disorders5/452/425/41
InfluenzaInfections and infestations2/451/425/41
Upper respiratory tract infectionInfections and infestations3/450/425/41
NauseaGastrointestinal disorders2/455/420/41
Back painMusculoskeletal and connective tissue disorders4/455/422/41
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders2/455/424/41

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw)IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw)Placebo (0.1% Albumin) 4 mL/kg bw/InfusionTotal
<=18 years0101
Between 18 and 65 years454141127
>=65 years0000
Age, Continuous
Age, Continuous(years)IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw)IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw)Placebo (0.1% Albumin) 4 mL/kg bw/InfusionTotal
Mean31.9 ± 7.534.4 ± 7.933.0 ± 8.733.1 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw)IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw)Placebo (0.1% Albumin) 4 mL/kg bw/InfusionTotal
Female38273196
Male7151032
Region of Enrollment
Region of Enrollment(participants)IGIV-C 0.2 g/kg bw/Infusion (2 mL/kg bw)IGIV-C 0.4 g/kg bw/Infusion (4 mL/kg bw)Placebo (0.1% Albumin) 4 mL/kg bw/InfusionTotal
United States53311
Czech Republic610622
Hungary4228
Greece1203
Canada51511
Poland106824
Austria3126
Israel1023
Germany9151135
United Kingdom1225
08

Study locations

37 sites
  • Barrow Neurological Institute at St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • Northwest NeuroSpecialists, PLLC
    Tucson, Arizona 85741-3537, United States
  • The Mt. Sinai Medical Center, Department of Neurology
    New York, New York 10029, United States
  • SUNY Health Science Center at Stony Brook, Department of Neurology
    Stony Brook, New York 11794-8121, United States
  • Wake Forest University - School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Neurology Health Care Service, Fletcher Allen Health Care
    Burlington, Vermont 05401, United States
  • Department of Neurology, Karl-Franzens University
    Graz, 8010, Austria
  • Foothills Hospital
    Calgary, Alberta T2N 2T9, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • The Ottawa Hospital, General Campus - Neurology Division
    Ottawa, Ontario K1H 8L6, Canada
  • CHUM Hospital Notre Dame
    Montreal, Quebec H2L4M1, Canada
  • Fakultni nemocnice Brno-Bohunice
    Brno, 63900, Czech Republic
  • St. Anna's Teaching Hospital
    Brno, 65691, Czech Republic
  • Všeobecná fakultní nemocnice
    Prague 2, 12808, Czech Republic
  • Department of Neurology, Motol Teaching Hospital
    Prague, 15600, Czech Republic
  • Medizinische Einrichtungen der Heinrich Heine Universitat, Neurologische Klinik
    Dusseldorf, 40225, Germany
  • HELIOS Klinikum Erfurt GmbH, Klinik und Poliklinik fur Neurologie
    Erfurt, 99089, Germany
  • Klinikum der Justus-Liebig-Universitat, Zentrum fur Neurologie und Neurochirurgie
    Giessen, Germany
  • Universitatsklinikum Munster, Klinik und Poliklinik fur Neurologie
    Munster, 48149, Germany
  • Klinikum Osnabrück GmbH
    Osnabrück, 49076, Germany
  • Universitatsklinikum Ulm, Poliklinik fur Neurologie
    Ulm, 89075, Germany
  • Klinijum der Universitat Wurzburg, Neurologische Klinik und Poliklinik
    Wurzburg, Germany
  • Henry Dunant Hospital
    Athens, 11526, Greece
  • Szent Imre Korhaz Neurologia
    Budapest, 115, Hungary
  • Uzsoki Street Hospital
    Budapest, H-1145, Hungary
  • Jahn Ferenc Delpesti Teaching Hospital
    Budapest, H-1204, Hungary
  • Szeged University of Science
    Szeged, H-5720, Hungary
  • Lady Davis Carmel Medical Center
    Haifa, 34362, Israel
  • Katedra I Klinika Neurologii; Slaskiej Akademii Medycznej, Samodzielny Publiczny Centralny Szpital Kliniczny
    Katowice-Ligota, 40-752, Poland
  • Katedra I Klinika Neurologii, Univerytetu Medycznego w Lodzi
    Lodz, 90-153, Poland
  • Katedra I Klinika Neurologii
    Lublin, 20-954, Poland
  • Klinika Neurologiczna, Wojskowy Instut Medyczny
    Warsaw, 00-909, Poland
  • Fakultna menocnica Bratislava
    Bratislava 2, 83-305, Slovakia
  • Dererova nemocnica s Poliklinikou Nerologicka Klinika
    Bratislava 2, 833 05, Slovakia
  • Lasarette Neurologiavdeling
    Lund, Sweden
  • Karilinska Sjukhuset
    Stockholm, Sweden
  • University Hospital, Queens Medical Centre
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Publications

  • Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sorensen PS, Maas-Enriquez M, Sommerauer B, Hanna K; PRIVIG Study Group; UBC MS/MRI Research Group. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology. 2008 Jul 22;71(4):265-71. doi: 10.1212/01.wnl.0000318281.98220.6f. PubMed 18645164 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002, a primary completion of Feb 2005 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 9 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 22, 2005
Start
Dec 2002
Primary completionActual
Feb 2005
CompletionActual
Feb 2005
Results first posted
Apr 11, 2014
Last update
Apr 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00220779
Responsible party
Sponsor
First posted
Sep 22, 2005
Start date
Dec 2002
Primary completion
Feb 2005
Completion
Feb 2005
Results posted
Apr 11, 2014
Last update
Apr 27, 2016

Study contacts

Fred D Lublin, MD
principal investigator · Mt Sinai Medical Center, New York, NY

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion